Cote d'Ivoire vs Tanzania: Treatment coverage for schistosomiasis

Cote d'Ivoire
27.2%
in 2024
Tanzania
35.7%
in 2024
Cote d'Ivoire rank
38th
Tanzania rank
35th

Treatment coverage for schistosomiasis over time

  • Cote d'Ivoire
  • Tanzania
020406080200720152024

How they compare

Tanzania currently reports 35.7% against 27.2% in Cote d'Ivoire, a difference of 8.5%.

That makes Tanzania's figure about 1.3 times Cote d'Ivoire's.

The two have swapped places 4 times across 14 shared years of data; in 2009 it was Tanzania ahead.

Cote d'Ivoire ranks 38th and Tanzania ranks 35th of 45 countries.

Across the 3 decades both report, Cote d'Ivoire averaged higher in 2 and Tanzania in 1.

Head to head by decade

Decade Cote d'Ivoire Tanzania Difference Ahead
2000s 0.1% 0.6% 0.6% Tanzania
2010s 37.2% 34.6% 2.7% Cote d'Ivoire
2020s 49.4% 29.2% 20.3% Cote d'Ivoire

Averages of every year both report within each decade.

Frequently asked questions

Which has higher treatment coverage for schistosomiasis, Cote d'Ivoire or Tanzania?
Tanzania, at 35.7% against 27.2% in Cote d'Ivoire as of 2024.
What is the difference in treatment coverage for schistosomiasis between Cote d'Ivoire and Tanzania?
8.5%, with Tanzania ahead.
How many years of comparable data are there for Cote d'Ivoire and Tanzania?
14 years are reported by both, from 2009 to 2024.
How do Cote d'Ivoire and Tanzania rank globally for treatment coverage for schistosomiasis?
Cote d'Ivoire ranks 38th and Tanzania ranks 35th of 45 countries.
Where does this data come from?
World Health Organization (2025) – with minor processing by Our World in Data, published as Treatment coverage for schistosomiasis. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Treatment coverage for schistosomiasis
Unit
%
Source
World Health Organization (2025) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
45 places, 573 data points, 2006–2024
Last refreshed

Drug coverage out of estimated population who require it.